#USA #Orlando #Edgewise Therapeutics #Sevasemten #Becker muscular dystrophy

Edgewise Therapeutics to Present Sevasemten Data at MDA 2026

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a prominent biopharmaceutical firm specializing in muscle diseases, has made headlines with its announcement of participation in the upcoming 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference. The event is set to take place from March 8-11 at the Hilton Orlando in Florida.

The company will host a dedicated lunch forum on March 9, designed to discuss critical insights about Becker muscular dystrophy. This meeting, titled "Elevating Becker Outcomes: Unlocking New Insights, Mobilizing Communities, and Redefining Care," will feature a panel of esteemed experts including Dr. Matthew Wicklund from UT Health San Antonio and Abby Bronson from Edgewise, who will present research discussing Becker natural history data, the necessity of community involvement, and frameworks for multi-disciplinary care.

In addition, the conference will showcase significant new data concerning the drug Sevasemten, which is currently being evaluated in clinical trials. This first-in-class oral fast skeletal myosin inhibitor offers a novel method of counteracting muscle damage associated with conditions like Becker and Duchenne muscular dystrophies. Notably, research from the MESA open-label extension trial will be highlighted, shedding light on the long-term efficacy and safety of Sevasemten.

Key Presentations at the Conference

Several scientific posters detailing findings related to Sevasemten will be presented during the conference:

• - Long-term stabilization of function in Becker: This poster will be presented by Dr. Craig M. McDonald, detailing how Sevasemten prevented functional decline over a span of 3.5 years in patients involved in the MESA trial.
• - Effects on cardiac function: Dr. Ben Barthel will discuss the impacts of Sevasemten on left ventricular ejection fraction (LVEF) and NT-proBNP levels in adult Becker muscular dystrophy patients.
• - Patient-focused development: Abby Bronson will share insights derived from interviews exploring the patient experience and meaningful treatment outcomes in Becker muscular dystrophy.
• - Research on female carriers: Dr. Luuli Tran will present findings on the muscle injury proteins in female carriers of BMD and DMD mutations, indicating how plasma ART3 levels can predict muscle loss progression.

The Edgewise therapeutic team aims to engage attendees in discussions that not only elevate awareness about Becker muscular dystrophy but also foster collaborative efforts towards better community support and care definitions.

Sevasemten: Innovations in Muscle Disease Treatment

Sevasemten represents a groundbreaking approach in muscle disease treatment. As it protects against muscle damage using a unique mechanism of action, it has garnered important regulatory recognitions, including FDA Orphan Drug Designation for both Becker and Duchenne muscular dystrophies, Rare Pediatric Disease Designation, and Fast Track approvals.

Edgewise Therapeutics is deeply committed to advancing these innovative therapies to transform the lives of patients grappling with muscle diseases. As they prepare for MDA's 2026 conference, the company invites all attendees to explore the advancements in research that hold promise for the future of muscular dystrophy treatment. For additional details on the conference agenda and Edgewise's presentations, visit MDA Conference and Edgewise's website.

This event represents a significant step towards not only enhancing treatment protocols for Becker muscular dystrophy but also ensuring a supportive environment for patients and their families. With an unwavering focus on innovation and community mobilization, Edgewise seeks to redefine care in neuromuscular diseases.